Meme Kanserinde Neoadjuvan Tedavi Sonrası Rezidüel İnvaziv Hastalıkta Sistemik Tedavi Seçimi
Referanslar
National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Breast Cancer, NCCN Evidence Blocks. Version 6.2026, July 29, 2026. (15/09/2026 tarihinde https://www.nccn.org/professionals/physician_gls/pdf/breast_blocks.pdf adresinden ulaşılmıştır).
Loibl S, André F, Bachelot T, et al. Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Annals of Oncology. 2024;35(2):159–182. doi:10.1016/j.annonc.2023.11.016.
Korde LA, Somerfield MR, Carey LA, et al. Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline. Journal of Clinical Oncology. 2021;39(13):1485–1505. doi:10.1200/JCO.20.03399.
Cortazar P, Zhang L, Untch M, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. The Lancet. 2014;384(9938):164–172. doi:10.1016/S0140-6736(13)62422-8. Yayımlanmış düzeltme: The Lancet. 2019;393(10175):986. doi:10.1016/S0140-6736(18)32772-7.
Yau C, Osdoit M, van der Noordaa M, et al. Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients. The Lancet Oncology. 2022;23(1):149–160. doi:10.1016/S1470-2045(21)00589-1.
Loibl S, Park YH, Shao Z, et al. Trastuzumab Deruxtecan in Residual HER2-Positive Early Breast Cancer. The New England Journal of Medicine. 2026;394(9):845–857. doi:10.1056/NEJMoa2514661. Yayımlanmış düzeltme: The New England Journal of Medicine. 2026;394(13):1352. doi:10.1056/NEJMx260006.
Symmans WF, Peintinger F, Hatzis C, et al. Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. Journal of Clinical Oncology. 2007;25(28):4414–4422. doi:10.1200/JCO.2007.10.6823.
Mittendorf EA, Jeruss JS, Tucker SL, et al. Validation of a novel staging system for disease-specific survival in patients with breast cancer treated with neoadjuvant chemotherapy. Journal of Clinical Oncology. 2011;29(15):1956–1962. doi:10.1200/JCO.2010.31.8469.
Tutt ANJ, Garber JE, Kaufman B, et al. Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer. The New England Journal of Medicine. 2021;384(25):2394–2405. doi:10.1056/NEJMoa2105215.
Loibl S, Huang CS, Mano MS, et al. Adjuvant trastuzumab emtansine in HER2-positive breast cancer patients with HER2-negative residual invasive disease in KATHERINE. npj Breast Cancer. 2022;8(1):106. doi:10.1038/s41523-022-00477-z.
Bedrosian I, Somerfield MR, Achatz MI, et al. Germline Testing in Patients With Breast Cancer: ASCO–Society of Surgical Oncology Guideline. Journal of Clinical Oncology. 2024;42(5):584–604. doi:10.1200/JCO.23.02225.
Pascual J, Attard G, Bidard FC, et al. ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group. Annals of Oncology. 2022;33(8):750–768. doi:10.1016/j.annonc.2022.05.520.
von Minckwitz G, Huang CS, Mano MS, et al. Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer. The New England Journal of Medicine. 2019;380(7):617–628. doi:10.1056/NEJMoa1814017.
Geyer CE Jr, Untch M, Huang CS, et al. Survival with Trastuzumab Emtansine in Residual HER2-Positive Breast Cancer. The New England Journal of Medicine. 2025;392(3):249–257. doi:10.1056/NEJMoa2406070.
Daiichi Sankyo, Inc. ENHERTU (fam-trastuzumab deruxtecan-nxki) prescribing information. Revised May 2026. DailyMed. (16/09/2026 tarihinde https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7e67e73e-ddf4-4e4d-8b50-09d7514910b6 adresinden ulaşılmıştır).
Untch M, Shao Z, Huang CS, et al. Secondary safety analysis of trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1) in DESTINY-Breast05: Clinical and demographic risk factors of interstitial lung disease (ILD) and radiation pneumonitis (RP). Journal of Clinical Oncology. 2026;44(16_suppl):516. ASCO Annual Meeting, kongre özeti. doi:10.1200/JCO.2026.44.16_suppl.516.
Chan A, Moy B, Mansi J, et al. Final Efficacy Results of Neratinib in HER2-positive Hormone Receptor-positive Early-stage Breast Cancer From the Phase III ExteNET Trial. Clinical Breast Cancer. 2021;21(1):80–91.e7. doi:10.1016/j.clbc.2020.09.014.
Alliance for Clinical Trials in Oncology. T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial. ClinicalTrials.gov. NCT04457596. (17/09/2026 tarihinde https://clinicaltrials.gov/study/NCT04457596 adresinden ulaşılmıştır).
Schmid P, Cortes J, Dent R, et al. Overall Survival with Pembrolizumab in Early-Stage Triple-Negative Breast Cancer. The New England Journal of Medicine. 2024;391(21):1981–1991. doi:10.1056/NEJMoa2409932.
Schmid P, Cortes J, Dent RA, et al. Neoadjuvant pembrolizumab or placebo plus chemotherapy followed by adjuvant pembrolizumab or placebo for high-risk early-stage TNBC: Final analysis results from the phase 3 KEYNOTE-522 study. Journal of Clinical Oncology. 2026;44(16_suppl):507. Kongre özeti. doi:10.1200/JCO.2026.44.16_suppl.507.
Korde LA, Somerfield MR, Hershman DL, et al. Use of Immune Checkpoint Inhibitor Pembrolizumab in the Treatment of High-Risk, Early-Stage Triple-Negative Breast Cancer: ASCO Guideline Rapid Recommendation Update. Journal of Clinical Oncology. 2022;40(15):1696–1698. doi:10.1200/JCO.22.00503.
Pusztai L, Denkert C, O’Shaughnessy J, et al. Event-free survival by residual cancer burden with pembrolizumab in early-stage TNBC: exploratory analysis from KEYNOTE-522. Annals of Oncology. 2024;35(5):429–436. doi:10.1016/j.annonc.2024.02.002.
Masuda N, Lee SJ, Ohtani S, et al. Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy. The New England Journal of Medicine. 2017;376(22):2147–2159. doi:10.1056/NEJMoa1612645.
Mayer IA, Zhao F, Arteaga CL, et al. Randomized Phase III Postoperative Trial of Platinum-Based Chemotherapy Versus Capecitabine in Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy: ECOG-ACRIN EA1131. Journal of Clinical Oncology. 2021;39(23):2539–2551. doi:10.1200/JCO.21.00976.
Garber JE, Cameron D, Campbell C, et al. Sustained benefit of adjuvant olaparib in women with germline BRCA1- and BRCA2-associated high-risk HER2-negative early breast cancer: Updated results from the OlympiA phase III trial. Annals of Oncology. 2026 Aug 24. Basım öncesi çevrim içi yayın. doi:10.1016/j.annonc.2026.08.002.
Park KH, Loibl S, Sohn J, et al. Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with early breast cancer. ESMO Open. 2024;9(5):102974. doi:10.1016/j.esmoop.2024.102974.
Conte PF, Dieci MV, Bisagni G, et al. A-BRAVE trial: a phase III randomized trial with anti-PD-L1 avelumab in high-risk triple-negative early breast cancer patients. Annals of Oncology. 2025;36(12):1492–1502. doi:10.1016/j.annonc.2025.08.005.
Gilead Sciences. Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63). ClinicalTrials.gov. NCT05633654. (17/09/2026 tarihinde https://clinicaltrials.gov/study/NCT05633654 adresinden ulaşılmıştır).
AstraZeneca. A Study of Dato-DXd With or Without Durvalumab Versus Investigator’s Choice of Therapy in Patients With Stage I–III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03). ClinicalTrials.gov. NCT05629585. (16/09/2026 tarihinde https://clinicaltrials.gov/study/NCT05629585 adresinden ulaşılmıştır).
Francis PA, Pagani O, Fleming GF, et al. Final outcomes of the SOFT and TEXT phase III trials in premenopausal hormone receptor-positive early breast cancer. Annals of Oncology. 2026 Jun 1. Basım öncesi çevrim içi yayın. doi:10.1016/j.annonc.2026.05.704.
Johnston S, Martin M, O’Shaughnessy J, et al. Overall survival with abemaciclib in early breast cancer. Annals of Oncology. 2026;37(2):155–165. doi:10.1016/j.annonc.2025.10.005.
Martin M, Hegg R, Kim SB, et al. Treatment With Adjuvant Abemaciclib Plus Endocrine Therapy in Patients With High-risk Early Breast Cancer Who Received Neoadjuvant Chemotherapy: A Prespecified Analysis of the monarchE Randomized Clinical Trial. JAMA Oncology. 2022;8(8):1190–1194. doi:10.1001/jamaoncol.2022.1488.
Slamon D, Lipatov O, Nowecki Z, et al. Ribociclib plus Endocrine Therapy in Early Breast Cancer. The New England Journal of Medicine. 2024;390(12):1080–1091. doi:10.1056/NEJMoa2305488.
Crown J, Stroyakovskii D, Yardley DA, et al. Adjuvant ribociclib plus nonsteroidal aromatase inhibitor therapy in patients with HR-positive/HER2-negative early breast cancer: 5-year follow-up of NATALEE efficacy outcomes and updated overall survival. ESMO Open. 2025;10(11):105858. doi:10.1016/j.esmoop.2025.105858.
Freedman RA, Caswell-Jin JL, Hassett M, et al. Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer—Cyclin-Dependent Kinase 4 and 6 Inhibitors: ASCO Guideline Rapid Recommendation Update. Journal of Clinical Oncology. 2024;42(18):2233–2235. doi:10.1200/JCO.24.00886.
Loibl S, Martin M, Bonnefoi H, et al. Final survival results from the PENELOPE-B trial investigating palbociclib versus placebo for patients with high-risk HR+/HER2− breast cancer and residual disease after neoadjuvant chemotherapy. Annals of Oncology. 2025;36(7):832–837. doi:10.1016/j.annonc.2025.03.010.
Bardia A, Schmid P, Martín M, et al. Abstract GS1-10: Giredestrant vs standard-of-care endocrine therapy as adjuvant treatment for patients with estrogen receptor-positive, HER2-negative early breast cancer: Results from the global Phase III lidERA Breast Cancer trial. Clinical Cancer Research. 2026;32(4_Supplement):GS1-10. Kongre özeti. doi:10.1158/1557-3265.SABCS25-GS1-10.